Profitable MorphoSys Proves Value of Technology Partnership Model
This article was originally published in The Pink Sheet Daily
A milestone payment from long-time partner Novartis helped German antibody company MorphoSys report record revenues, supporting a 23% increase in R&D spend without the need to tap investors.
You may also be interested in...
MorphoSys sells some of its assets in an effort to concentrate on its proprietary therapeutic endeavors – including a mid-stage rheumatoid arthritis drug.
As its pharma division separates from its diversified medical products unit, Abbott obtains another drug that could succeed Humira in rheumatoid arthritis and related indications.
After searching a year and a half for the right compound to complete its proprietary pipeline, German MorphoSys completed a biotech-biotech deal with a simpatico California company.